Stock Market Impact: Shares of ADC Therapeutics SA dropped 45.9% in after‑hours trading following release of Phase 3 LOTIS‑5 topline data.
Listed Companies and Sectors: The biotech/pharma company reported trial results for ZYNLONTA + rituximab in relapsed/refractory diffuse large B‑cell lymphoma, affecting the Pharma / Healthcare sector.
Investment Flows: No specific information on FDI/FPI or capital flows was provided.
Interest Rates, Inflation, and Liquidity: No mention of monetary policy or liquidity measures.
Fiscal or Monetary Policy: No fiscal or monetary policy actions were discussed.
